Newsletter
Zydus Lifesciences is stepping up its U.S. biosimilars push. Its arm, Zydus Lifesciences Global FZE, has entered into a strategic partnership with Swiss biopharma firm Bioeq AG to license, supply, and commercialise NUFYMCO.
What’s poppin’: NUFYMCO is a lower-cost, FDA-approved alternative to Lucentis, used to treat serious eye conditions.
Under the deal, Zydus Lifesciences Global FZE, which is based in the UAE, will take charge of commercialising the drug in the U.S. Bioeq will handle the development, manufacturing, regulatory approvals, and supply role.
It marks another step in Zydus’ expanding U.S. biosimilars business, coming close on the heels of its recent tie-up with Formycon AG for a biosimilar of Keytruda.
Zoom out: the U.S. biosimilars market is becoming a major force in healthcare. Since 2015, biosimilars have delivered over $56 billion in savings, with $20.2 billion saved in 2024 alone. As more than 100 biologic drugs are set to lose patent protection by 2034, the opportunity for lower-cost alternatives is expanding fast.
High-cost therapies like eye and cancer treatments are leading this shift, which explains why companies like Zydus are scaling up their U.S. biosimilar presence through partnerships.
